natgillin/translations-raw huggingface dataset:
Travatan is a clear eye drop solution that contains the active substance travoprost. 
Zdravilo Travatan je bistra raztopina v obliki kapljic za oko, ki vsebuje zdravilno učinkovino travoprost.
What is Travatan used for? 
Za kaj se zdravilo Travatan uporablja?
How is Travatan used? 
Kako se zdravilo Travatan uporablja?
What is Travatan? 
Kaj je zdravilo Travatan?
Travatan acts in the same way and increases the flow of fluid out of the eye. 
Zdravilo Travatan deluje enako in poveča odtok tekočine iz očesa, s čimer pomaga znižati očesni tlak.
50 mg Powder for concentrate for solution for injection / infusion 
50 mg prašek za koncentrat za raztopino za injiciranje / infundiranje intravenska uporaba
Invented name 
Številka EU Izmišljeno ime
Intravenous use Vial (glass) 
Viala (steklo)
It is used: 
Uporablja se:
The remaining 16 patients did not fall into either group. 
Preostalih 16 bolnikov ni spadalo v nobeno od omenjenih skupin.
This was switched to a full marketing authorisation on 24 April 2015. 
To je bilo 24. aprila 2015 spremenjeno v običajno dovoljenje za promet.
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Arzerra on 19 April 2010. 
Evropska komisija je pogojno dovoljenje za promet z zdravilom Arzerra, veljavno po vsej Evropski uniji, izdala 19. aprila 2010.
What measures are being taken to ensure the safe and effective use of Arzerra? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Arzerra?
The main measure of effectiveness was the number of patients who ‘responded' to treatment. 
Glavno merilo učinkovitosti je bil število bolnikov, ki so se odzvali na zdravljenje.
It is given using an infusion pump. 
Daje se s pomočjo infuzijske črpalke.
To reduce the risk of these reactions, infusions are started slowly (particularly when first starting treatment) and then speeded up every 30 minutes if no reactions occur. 
Da bi zmanjšali tveganje za pojav teh neželenih učinkov, je infundiranje sprva počasno (zlasti na začetku zdravljenja), nato pa se vsakih 30 minut pospeši, če ni reakcij.
This is a summary of the European Public Assessment Report (EPAR) for Arzerra. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Arzerra.
As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval. 
Ko je družba predložila dodatne zahtevane podatke, je bilo dovoljenje za promet spremenjeno iz pogojnega v običajno.
Other information about Arzerra 
Druge informacije o zdravilu Arzerra
Arzerra was originally given ‘conditional approval', because there was more evidence to come about the medicine. 
Zdravilo Arzerra je prvotno pridobilo „pogojno dovoljenje za promet“, ker so bili pričakovani dodatni dokazi o zdravilu.
If reactions occur, treatment is interrupted and may be restarted at a slower rate when the patient has recovered or stopped permanently if a serious allergic reaction occurs. 
Če pride do reakcij, se zdravljenje prekine in se lahko ponovno začne počasneje, ko si bolnik opomore, ali se trajno prekine, če pride do resnih alergijskih reakcij.
The dosing schedule depends on whether the patient has been treated before and whether the patient's disease has come back. 
Shema odmerjanja je odvisna od tega, ali je bil bolnik predhodno že zdravljen in ali se je bolezen ponovila.
The European Medicines Agency decided that the medicine's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Evropska agencija za zdravila je sklenila, da so koristi zdravila Arzerra večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
The summary of the opinion of the Committee for Orphan Medicinal Products for Arzerra can also be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Arzerra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
What benefits of Arzerra have been shown in studies? 
Kakšne koristi je zdravilo Arzerra izkazalo v študijah?
It is not intended to provide practical advice on how to use of Arzerra. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Arzerra? 
Kakšna tveganja so povezana z zdravilom Arzerra?
What is Arzerra and what is it used for? 
Kaj je zdravilo Arzerra in za kaj se uporablja?
Arzerra was not compared with any other treatments in this study. 
V tej študiji zdravila Arzerra niso primerjali z drugimi zdravili.
For practical information about using Arzerra, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Arzerra naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Arzerra have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Arzerra upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Arzerra approved? 
Zakaj je bilo zdravilo Arzerra odobreno?
The full EPAR for Arzerra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Arzerra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in certain cells in the body. 
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna določeno strukturo (imenovano antigen), ki je prisotna v nekaterih celicah v telesu, in se veže nanjo.
Because the number of patients with CLL is low, the disease is considered ‘rare', and Arzerra was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 November 2008. 
Ker je bolnikov s kronično limfocitno levkemijo malo, velja ta bolezen za redko, zato je bilo zdravilo Arzerra 7. novembra 2008 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
The response rate was slightly lower in patients whose treatment with fludarabine had failed but who were not suitable for treatment with alemtuzumab (43%). 
Stopnja odzivnosti je bila nekoliko nižja pri bolnikih, pri katerih je bilo zdravljenje s fludarabinom neuspešno in ki niso bili primerni za zdravljenje z alemtuzumabom (43 %).
Arzerra can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in treating cancer and in a place where facilities for resuscitating patients are readily available. 
Predpisovanje in izdaja zdravila Arzerra je le na recept, dajati pa ga je treba pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem raka, v ustanovi, v kateri je nemudoma na voljo oprema za oživljanje.
In patients whose previous treatment with both fludarabine and alemtuzumab had failed, 49% (47 out of 95) responded to treatment with Arzerra. 
Pri bolnikih, katerih predhodno zdravljenje s fludarabinom in alemtuzumabom ni bilo uspešno, se jih je 49 % (47 od 95) odzvalo na zdravljenje z zdravilom Arzerra.
The Agency also noted that patients with CLL who had not responded to previous treatment have limited treatment options. 
Prav tako je ugotovila, da imajo bolniki s kronično limfocitno levkemijo, ki se niso odzvali na predhodno zdravljenje, omejene možnosti zdravljenja.
In 95 of these patients, the disease had not responded to both fludarabine and alemtuzumab, and in 112, treatment with fludarabine had failed but the patients had not been treated with alemtuzumab because this medicine was not suitable for them. 
Od teh bolnikov se jih 95 ni odzvalo na zdravljenje s fludarabinom in alemtuzumabom, pri 112 pa je bilo zdravljenje s fludarabinom neuspešno, z alemtuzumabom pa jih niso zdravili, saj to zdravilo zanje ni bilo primerno.
In these patients Arzerra is used together with fludarabine and cyclophosphamide. 
Pri teh bolnikih se zdravilo Arzerra uporablja skupaj s fludarabinom in ciklofosfamidom.
The most common side effects with Arzerra (seen in more than 1 patient in 10) are lower respiratory tract infection (infection of the lungs such as pneumonia), upper respiratory tract infection (nose and throat infection), neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts), nausea (feeling sick), fever, rash, dyspnoea (difficulty breathing), cough, diarrhoea and tiredness. 
Najpogostejši neželeni učinki zdravila Arzerra (opaženi pri več kot 1 bolniku od 10) so okužba spodnjih dihal (okužba pljuč, kot je pljučnica), okužbe zgornjih dihal (okužbe nosu in grla), nevtropenija (nizko število nevtrofilcev, vrste belih krvnih celic), anemija (nizko število rdečih krvnih celic), navzeja (slabost), povišana telesna temperatura, izpuščaji, dispneja (oteženo dihanje), kašelj, driska in utrujenost.
By attaching to CD20, ofatumumab stimulates the body's immune system to attack the cancerous cells, helping to control the disease. 
Ofatumumab z vezavo na CD20 spodbudi imunski sistem, da napade rakave celice, kar pripomore k obvladovanju bolezni.
• in patients whose disease has come back after previous treatment (known as relapsed disease). 
• pri bolnikih, katerih bolezen se je po predhodnem zdravljenju ponovno pojavila (ponovljena bolezen).
Before each infusion, the patient receives medicines, such as a corticosteroid, an antihistamine and paracetamol, to help to prevent infusion reactions (such as rash, fever, allergic reactions and difficulty breathing). 
Pred vsako infuzijo mora bolnik prejeti zdravila, kot je kortikosteroid, antihistaminik in paracetamol, kar pripomore k preprečevanju neželenih učinkov pri infundiranju (kot so izpuščaji, povišana telesna temperatura, alergijske reakcije in oteženo dihanje).
Arzerra is a cancer medicine used to treat adults with chronic lymphocytic leukaemia (CLL), a cancer of a type of white blood cells called lymphocytes. 
Arzerra je zdravilo za zdravljenje raka, ki se uporablja pri odraslih s kronično limfocitno levkemijo (KLL), tj. rakom vrste belih krvnih celic, imenovanih limfociti.
The response to treatment was assessed by looking at the patients' symptoms, the number of lymphocytes in their blood, results of blood and bone marrow tests and the size of their lymph nodes, liver and spleen. 
Odziv na zdravljenje so ocenili glede na simptome bolnikov, število limfocitov v krvi, rezultate krvnih preiskav in preiskav kostnega mozga ter velikost bezgavk, jeter in vranice.
For more information on how Arzerra is used, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Arzerra glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
• in previously untreated patients who cannot be treated with fludarabine; in these patients it is used together with chlorambucil or bendamustine (other cancer medicines); 
• pri predhodno nezdravljenih bolnikih, ki jih ni mogoče zdraviti s fludarabinom; pri teh bolnikih se zdravilo Arzerra uporablja skupaj s klorambucilom ali bendamustinom (drugima zdraviloma za zdravljenje raka);
The Agency noted that Arzerra was shown to be effective at treating patients with CLL (previously untreated patients, patients who had not responded to previous treatment with fludarabine and alemtuzumab and patients whose cancer had come back after previous treatment). 
Ugotovila je, da se je zdravilo Arzerra izkazalo kot učinkovito pri zdravljenju bolnikov s kronično limfocitno levkemijo (predhodno nezdravljenih bolnikov, bolnikov, ki se niso odzvali na zdravljenje s fludarabinom in alemtuzumabom, in bolnikov, pri katerih se je rak po predhodnem zdravljenju ponovil).
For the full list of side effects and restrictions with Arzerra, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Arzerra glejte navodilo za uporabo.
Arzerra is available as a concentrate that is made up into a solution for infusion (drip) into a vein. 
Zdravilo Arzerra je na voljo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
For more information about treatment with Arzerra, read the Package Leaflet (also part of the EPAR). 
Za več informacij o zdravljenju z zdravilom Arzerra preberite navodilo za uporabo (ki je prav tako del EPAR).
Ofatumumab has been designed to attach to a protein called CD20 that is found on the surface of lymphocytes, including the cancerous lymphocytes seen in CLL. 
Ofatumumab je bil zasnovan tako, da se veže na beljakovino, imenovano CD20, ki jo najdemo na površini limfocitov, vključno z rakavimi limfociti, prisotnimi pri kronični limfocitni levkemiji.
The active substance in Arzerra, ofatumumab, is a monoclonal antibody. 
Zdravilna učinkovina v zdravilu Arzerra, ofatumumab, je monoklonsko protitelo.
Arzerra has been investigated in one main study involving 223 patients with CLL whose disease had not responded to previous treatment. 
Zdravilo Arzerra so proučevali v eni glavni študiji, v katero je bilo vključenih 223 bolnikov s kronično limfocitno levkemijo, ki se ni odzvala na predhodno zdravljenje.
Arzerra plus fludarabine and cyclophosphamide was effective at increasing progression-free survival, with patients living on average for 28.9 months without their disease getting worse, compared with 18.8 months in patients given fludarabine and cyclophosphamide alone. 
Zdravilo Arzerra v kombinaciji s fludarabinom in ciklofosfamidom je bilo učinkovito pri podaljševanju časa preživetja bolnikov brez napredovanja bolezni, pri čemer so bolniki brez poslabšanja bolezni v povprečju živeli 28,9 meseca, medtem ko je to obdobje pri bolnikih, ki so prejemali fludarabin in ciklofosfamid, znašalo 18,8 meseca.
One main study involving 365 patients whose cancer had come back compared the combination of Arzerra plus fludarabine and cyclophosphamide with fludarabine and cyclophosphamide used alone. 
V glavni študiji, v katero je bilo vključenih 365 bolnikov, pri katerih se je rak ponovil, so kombinacijo zdravila Arzerra in fludarabina ter ciklofosfamida primerjali s kombinacijo fludarabina in ciklofosfamida kot samostojnima zdraviloma.
Arzerra plus chlorambucil was effective at increasing progression-free survival (how long the patients lived without their disease getting worse), with patients living on average for 22.4 months without their disease getting worse, compared with 13.1 months in patients given chlorambucil alone. 
Kombinacija zdravila Arzerra in klorambucila je bila učinkovita pri podaljševanju časa preživetja brez napredovanja bolezni (obdobja preživetja bolnikov brez poslabšanja bolezni), pri čemer so bolniki v povprečju živeli 22,4 meseca brez poslabšanja bolezni, medtem ko je bilo to obdobje pri bolnikih, ki so jemali samo klorambucil, 13,1.
How does Arzerra work? 
Kako zdravilo Arzerra deluje?
One main study involving 447 previously untreated patients who could not be treated with fludarabinebased therapy compared a combination of Arzerra plus chlorambucil with chlorambucil given alone. 
V eni glavni študiji, v kateri je sodelovalo 447 predhodno nezdravljenih bolnikov, ki jih ni bilo mogoče zdraviti s fludarabinom, so kombinacijo zdravila Arzerra in klorambucila primerjali s klorambucilom kot samostojnim zdravilom.
How is Arzerra used? 
Kako se zdravilo Arzerra uporablja?
• in patients whose disease has not responded to previous treatment (known as refractory disease) 
• pri bolnikih, katerih bolezen se ni odzvala na predhodna zdravljenja (neodzivna bolezen) s fludarabinom in alemtuzumabom;
Previously untreated CLL 
Predhodno nezdravljena kronična limfocitna levkemija
Refractory CLL 
Ponovljena kronična limfocitna levkemija
Arzerra contains the active substance ofatumumab. 
Zdravilo Arzerra vsebuje zdravilno učinkovino ofatumumab.
The symptoms were completely reversible. 
Ti znaki so bili popolnoma reverzibilni.
The potential clinical consequences of such interactions have not been investigated. 
Možne klinične posledice takega medsedbojnega delovanja še niso raziskane.
For external use only. 
Samo za zunanjo uporabo.
{leave space for the date to be inserted}. 
{pustite prostor za vpis datuma}
The excretion of emodepside has not been investigated in dogs. 
Izločanje emodepsida pri psih ni bilo raziskano.
ATCvet code: QP52AA51. 
Oznaka ATCvet: QP52AA51.
Wash hands after use. 
Po dajanju si umijte roke.
Remove screw cap (2). 
Odstranite navojno zaporko (2).
Bayer Hungária Kft. HU-1123 Budapest Alkotás u. 50 
Magyarország Bayer Hungária Kft. HU-1123 Budapest Alkotás u. 50
Treated animals therefore should not be bathed until the solution has dried. 
Zdravljene živali ne kopamo, dokler se raztopina ne posuši.
No studies have been performed with severely debilitated dogs or individuals with seriously compromised kidney or liver function. 
Študije niso bile opravljene na močno oslabljenih psih ali psih z močno okrnjenim delovanjem ledvic ali jeter.
Keep children away from treated animals during that time. 
V tem času preprečite otrokom stik z zdravljeno živaljo.
Specific antidotes are not known. 
Specifični protistrupi niso znani.
The symptoms were completely self-resolving without any treatment. 
Ti znaki so popolnoma izginili brez zdravljenja.
Both active substances were then eliminated from the plasma with a half-life of 1.4 to 1.7 hours. 
Obe učinkovini sta se izločili iz plazme z razpolovnim časom 1,4 do 1,7 ure.
Pharmacotherapeutic group: therapeutic antiparasitic agent. 
Farmakoterapevtska skupina: terapevtski antiparazitik.
Do not smoke, eat or drink during application. 
Med nanosom ne jejte, pijte in kadite.
Care should be taken not to allow children to have prolonged intensive contact (for example, by sleeping) with treated cats during the first 24 hours after application of the product. 
Otroci naj ne bi bili v daljšem, intenzivnem stiku (npr. spali) z zdravljenimi mačkami v prvih 24 urah po nanosu zdravila.
Incompatibilities: None known. 
Inkompatiilnosti: Niso znane.
Emodepside is a semi-synthetic compound belonging to the new chemical group of depsipeptides. 
Emodepsid je polsintetična spojina, ki spada v novo kemično skupino depsipeptidov.
Date of last renewal: 01/07/2010. 
Datum podaljšanja dovoljenja za promet: 01/07/2010.
Maximum concentrations were reached 2 hours after treatment for both active substances. 
Najvišja koncentracija obeh učinkovin je bila dosežena 2 uri po dajanju.
Emodepside is a substrate for P-glycoprotein. 
Emodepsid je substrat za P-glikoprotein.
It acts at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family which results in paralysis and death of the parasites. 
Deluje na živčno-mišičnem stiku tako, da draži presinaptične receptorje, ki spadajo v družino sekretinskih receptorjev, kar povzroči paralizo in pogin zajedavca.
Studies in many different species show that praziquantel is rapidly metabolised in the liver. 
Raziskave na večih različnih živalskih vrstah so pokazale, da se prazikvantel hitro presnovi v jetrih.
Appropriate combination of volumes 
Ustrezna kombinacija količin
1 = 3 kg medium dogs = 10 kg large dogs = 30 kg 
1 = 3 kg srednje veliki psi = 10 kg veliki psi = 30 kg
Then turn bottle up-side down, and withdraw the necessary volume (4). 
Nato obrnite steklenico in izvlecite potrebno količino zdravila (4).
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. 
Zajedavci lahko razvijejo odpornost proti kateremu koli razredu antihelmintika, po pogosti, ponavljajoči uporabi antihelmintika istega razreda.
For the lungworm Aelurostrongylus abstrusus, two treatments administered two weeks apart are effective. 
Za zdravljenje pljučnega črva Aelurostrongylus abstrusus sta učinkovita dva tretmaja, ki ju damo z dvotedenskim razmikom.
Pregnancy and lactation: Profender can be used during pregnancy and lactation. 
Brejost in laktacija: Zdravilo Profender se lahko uporablja v obdobju brejosti in laktacije.
Profender should not be allowed to enter water courses as emodepside has shown harmful effects on aquatic organisms. 
Zdravilo Profender ne sme priti v vodotoke, ker je emodepsid nevaren za vodne organizme.
Volume (ml) 
Količina (ml)
Therefore, the veterinary medicinal product should only be used in such animals according to a benefit/risk assessment by the responsible veterinarian. 
Pri teh psih zdravilo uporabite samo v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
Do not administer orally or parenterally. 
Zdravila ne dajajte peroralno ali parenteralno.
Echinococcosis represents a hazard for humans. 
Ehinokokoza predstavlja za človeka resno zdravstveno tveganje.
Then turn bottle up-side down, and withdraw the necessary volume. 
Nato obrnite steklenico in izvlecite potrebno količino zdravila.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastajajo iz teh zdravil, je treba odstraniti v skladu z lokalnimi zahtevami.
There is no known specific antidote. 
Specifični protistrup ni znan.
Either calculate the exact dose based on the individual body weight, or use the following dose volumes recommended for the different weight ranges: 
Preračunajte ustrezen odmerek na osnovi telesne mase ali pa uporabite priporočene količine za ustrezen razpon telesnih mas.
Shampooing or immersion of the animal in water directly after treatment may reduce the efficacy of the product. 
Umivanje s šamponom ali stik živali z vodo neposredno po nanosu zdravila lahko zmanjšata njegovo učinkovitost.
Φλέμινγκ 15 EL-15123 Μαρούσι - Αθήνα 
EL-15123 Μαρούσι - Αθήνα Τηλ.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients. 
Ne uporabite v primerih preobčutljivosti na učinkovine ali na katero koli pomožno snov.
For example: Overnight fasting if the dog is to be treated in the morning. 
Priporočamo postenje psa preko noči, če mu boste dali tableto zjutraj.
For the treatment of queens to prevent lactogenic transmission of Toxocara cati (L3 larvae) to the offspring, a single administration per treatment approximately seven days prior to expected parturition is effective. 
Za zdravljenje mačk, da se prepreči laktogeni prenos Toxocara cati (ličinke L3) na potomce, je učinkovito zdravljenje po enkratnem dajanju približno sedem dni pred pričakovano kotitvijo.
QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Učinkovine:
Special precautions for use in animals: Apply only to the skin surface and on intact skin. 
Posebni previdnostni ukrepi za uporabo pri živalih: Zdravilo nanesite le na nepoškodovano kožo.
In the interests of good hygiene, wash your hands after administering the tablets to the dog. 
Iz higienskih razlogov si po dajanju tablet umijte roke.
Active substances: 
Pomožne snovi:
Tapeworms (Cestodes) 
Trakulje (Cestodi)
This results in severe damage to the parasite integument, contraction and paralysis, disruption of metabolism and finally leads to the death of the parasite. 
Posledica tega so hude poškodbe zajedavčeve povrhnjice, spazem in paraliza, prekinitev presnove in v zadnji fazi pogin zajedavca.
For oral use in dogs from 12 weeks of age and weighing at least 1 kg. Profender tablets are meat flavoured and usually dogs will accept them without any food. 
Zdravilo dajemo peroralno psom, starejšim od 12 tednov in s telesno maso najmanj 1 kg. Tablete Profender imajo okus po mesu, zato jih psi običajno radi pojedo brez dodatne hrane.
If the product accidentally gets into eyes, they should be thoroughly flushed with plenty of water. 
Če zdravilo pride v stik z očmi, jih temeljito sperite z vodo.